Associated Papers
Gene therapy targeting synaptopathy linked with Alzheimer's and Parkinson's disease.
Panda SP et al.
Neuroscience, 2026
Alpha-Synuclein Neurobiology in Parkinson's Disease: A Comprehensive Review of Its Role, Mechanisms, and Therapeutic Perspectives.
Pitton Rissardo J et al.
Brain Sciences, 2025
The Aggregation Continuum of α-Synuclein and Its Relevance to Brain Aging.
Rana A et al.
Acs Chemical Neuroscience, 2025
Synaptic sabotage: How Tau and α-Synuclein undermine synaptic health.
Uytterhoeven V et al.
The Journal of Cell Biology, 2025
The Role of Astrocytes and Alpha-Synuclein in Parkinson's Disease: A Review.
Brash-Arias D et al.
Neurosci, 2024
TOLLIP acts as a cargo adaptor to promote lysosomal degradation of aberrant ER membrane proteins.
Hayashi Y et al.
The Embo Journal, 2023
Interaction Between the Glymphatic System and α-Synuclein in Parkinson's Disease.
Zhang Y et al.
Molecular Neurobiology, 2023
Pharmacological PINK1 activation ameliorates Pathology in Parkinson's Disease models.
Chin RM et al.
Biorxiv : the Preprint Server for Biology, 2023
miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson's disease.
Suvarna V et al.
Frontiers in Pharmacology, 2022
Deficient immunoproteasome assembly drives gain of α-synuclein pathology in Parkinson's disease.
Bi M et al.
Redox Biology, 2021
Cytosolic aggregation of mitochondrial proteins disrupts cellular homeostasis by stimulating the aggregation of other proteins.
Nowicka U et al.
Elife, 2021
Targeting of Lysosomal Pathway Genes for Parkinson's Disease Modification: Insights From Cellular and Animal Models.
Abe T et al.
Frontiers in Neurology, 2021
Single-Cell Transcriptomics of Parkinson's Disease Human In Vitro Models Reveals Dopamine Neuron-Specific Stress Responses.
Fernandes HJR et al.
Cell Reports, 2020
Dynamin-related protein 1: A protein critical for mitochondrial fission, mitophagy, and neuronal death in Parkinson's disease.
Feng ST et al.
Pharmacological Research, 2020
Pathogenic Mutations Differentially Regulate Cell-to-Cell Transmission of α-Synuclein.
Guan Y et al.
Frontiers in Cellular Neuroscience, 2020
Replication of multiple system atrophy prions in primary astrocyte cultures from transgenic mice expressing human α-synuclein.
Krejciova Z et al.
Acta Neuropathologica Communications, 2019
What is the Evidence That Parkinson's Disease is a Prion Disorder, Which Originates in the Gut?
Kujawska M et al.
International Journal of Molecular Sciences, 2018
Mitochondrial dysfunction and neurodegenerative proteinopathies: mechanisms and prospects for therapeutic intervention.
Briston T et al.
Biochemical Society Transactions, 2018
α-synuclein Induces Mitochondrial Dysfunction through Spectrin and the Actin Cytoskeleton.
Ordonez DG et al.
Neuron, 2018
Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease.
Zeng XS et al.
Frontiers in Aging Neuroscience, 2018
Alpha-synuclein at the intracellular and the extracellular side: functional and dysfunctional implications.
Ottolini D et al.
Biological Chemistry, 2017
Glia and alpha-synuclein in neurodegeneration: A complex interaction.
Brück D et al.
Neurobiology of Disease, 2016
Single-molecule FRET studies on alpha-synuclein oligomerization of Parkinson's disease genetically related mutants.
Tosatto L et al.
Scientific Reports, 2015
Link between the SNCA gene and parkinsonism.
Xu W et al.
Neurobiology of Aging, 2015
Genetic variants and animal models in SNCA and Parkinson disease.
Deng H et al.
Ageing Research Reviews, 2014
Limelight on alpha-synuclein: pathological and mechanistic implications in neurodegeneration.
Wales P et al.
Journal of Parkinson's Disease, 2013
Macroautophagy in sporadic and the genetic form of Parkinson's disease with the A53T α-synuclein mutation.
Huang Y et al.
Translational Neurodegeneration, 2012
New animal models of Parkinson's disease.
Dehay B et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2011
Mouse models of cognitive deficits due to alpha-synuclein pathology.
Magen I et al.
Journal of Parkinson's Disease, 2011
Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.
Lin X et al.
Neuron, 2009
Novel suppressors of alpha-synuclein toxicity identified using yeast.
Liang J et al.
Human Molecular Genetics, 2008
Increased dopaminergic neuron sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in transgenic mice expressing mutant A53T alpha-synuclein.
Yu WH et al.
Neurochemical Research, 2008
Alpha-synuclein overexpression increases cytosolic catecholamine concentration.
Mosharov EV et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience, 2006
PA700, the regulatory complex of the 26S proteasome, interferes with alpha-synuclein assembly.
Ghee M et al.
The Febs Journal, 2005
Alpha-synuclein targets the plasma membrane via the secretory pathway and induces toxicity in yeast.
Dixon C et al.
Genetics, 2005
Pathogenic effects of alpha-synuclein aggregation.
Lundvig D et al.
Brain Research. Molecular Brain Research, 2005
Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease.
Dev KK et al.
Neuropharmacology, 2003
Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice.
Gomez-Isla T et al.
Neurobiology of Aging, 0